Search academic texts

Information × Registration Number 0222U000488, 0118U007361 , R & D reports Title To develop technology of antimycobacterial therapy with use of new drugs in patients with resistant lung tuberculosis popup.stage_title Head Lytvynenko Nataliia A, Registration Date 11-01-2022 Organization State organization "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky National academy of medical sciences of Ukraine" popup.description2 Aim: to determine optimal algorithms for prescribing reduced and individualized regimens for antimycobacterial therapy for patients with chemoresistant pulmonary tuberculosis, which will improve treatment efficiency and save public money. Methods: clinical, radiological, laboratory, microbiological. It was found that in patients with XDR, who according to the results of fDST are sensitive to fluoroquinolones, in 23,3–41,3% of cases, resistance to gDST is determined. The MBT resistance profile was studied, the tendency to increase the primary resistance to fluoroquinolones from 0 % to 30,0 % was established. Compared direct and long-term results of 2 modified shortened regimens with the inclusion of new drugs: bedaquiline-based regimens with the inclusion of moxifloxacin or levofloxacin and clofazimine, lead to successful treatment without recurrence for 24 months in all patients, with better tolerability of the moxifloxacin regimen. It is established that the use of advanced individualized regimens of 12–13 months lasts successful treatment in 88,6-91,3 % of patients - without recurrence within 12–24 months. The effect of psychological support and video-DOT, which reduced breaks in treatment by 9,1 %, was studied. Algorithms for use as modified shortened or individualized regimens have been developed, based on gDST, history of previous treatment and prevalence of destructive changes in the lungs. A method of treating patients with rifampicin-resistant pulmonary TB was developed, which increased the frequency of bacterial cessation and disappearance of clinical manifestations by 11,7 %, reduced by 32,9 % progression and the incidence of PR by 13,6 %. Sphere of application – tuberculosis. Product Description popup.authors Isaakidi Petros Alex Kim Barbova Anna Blyznyuk Oleksandr P Veselovsky Leonid Viktorovych Vorobchenko Tetyana M Heidi Suzanne Nigus Gomez Fabianola Gordiyo Hritsova Nataliya A Hrankina Nataliia V Didyk Vitaliy S Davydenko Valentyna V Donchuk Dmytro Yu Zhurilo Oleksandr A Zaykov Sergiy Viktorovich Zaytseva Olʹha S Korotchenko Svitlana P Kuzhko Mykhaylo M Lafeta Anastasiya S Marve Decavez Duca Pohrebna Maryna V Protsyk Lyubomyr M Siomak Olʹha V Senʹko Yuliya O Terleyeva Yana S Furin Jennifer Khachatur Malakyan Chinmay Shankar L Chobotar Oksana P Shcherbakova Lesya V popup.nrat_date 2022-03-09 Close